Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Juvenile Myelomonocytic Leukemia
|
0.810 | CausalMutation | CLINVAR | ||||||||
RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER
|
0.800 | CausalMutation | CLINVAR | ||||||||
Noonan Syndrome 6
|
0.700 | CausalMutation | CLINVAR | ||||||||
melanoma
|
0.700 | CausalMutation | CLINVAR | N-ras mutations in human cutaneous melanoma from sun-exposed body sites. | 2674680 | 1989 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | N-ras mutations in human cutaneous melanoma from sun-exposed body sites. | 2674680 | 1989 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | N-ras mutations in human cutaneous melanoma from sun-exposed body sites. | 2674680 | 1989 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Ras mutations in human melanoma: a marker of malignant progression. | 8120410 | 1994 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Ras mutations in human melanoma: a marker of malignant progression. | 8120410 | 1994 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Ras mutations in human melanoma: a marker of malignant progression. | 8120410 | 1994 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Distinct sets of genetic alterations in melanoma. | 16291983 | 2005 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Distinct sets of genetic alterations in melanoma. | 16291983 | 2005 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Distinct sets of genetic alterations in melanoma. | 16291983 | 2005 | |||||
Juvenile Myelomonocytic Leukemia
|
0.810 | GeneticVariation | UNIPROT | Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. | 17332249 | 2007 | |||||
RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER
|
0.800 | GeneticVariation | UNIPROT | NRAS mutation causes a human autoimmune lymphoproliferative syndrome. | 17517660 | 2007 | |||||
Autoimmune Lymphoproliferative Syndrome
|
0.020 | GeneticVariation | BEFREE | We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis. | 17517660 | 2007 | |||||
Hematologic Neoplasms
|
0.010 | GeneticVariation | BEFREE | We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis. | 17517660 | 2007 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. | 18375819 | 2008 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | 18390968 | 2008 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | 18390968 | 2008 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | 18390968 | 2008 | |||||
Leukemia, Myelocytic, Acute
|
0.700 | GeneticVariation | CLINVAR | Recurring mutations found by sequencing an acute myeloid leukemia genome. | 19657110 | 2009 | |||||
Leukemia, Myelocytic, Acute
|
0.700 | GeneticVariation | CLINVAR | Recurring mutations found by sequencing an acute myeloid leukemia genome. | 19657110 | 2009 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. | 20130576 | 2010 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. | 20130576 | 2010 | |||||
melanoma
|
0.700 | CausalMutation | CLINVAR | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. | 20130576 | 2010 |